Bio-Techne Co. (NASDAQ:TECH) Director Amy E. Herr Sells 1,860 Shares

Bio-Techne Co. (NASDAQ:TECH) Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the transaction, the director now directly owns 1,976 shares in the company, valued at $130,336.96. This represents a 48.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bio-Techne Price Performance

Shares of NASDAQ:TECH opened at $65.29 on Wednesday. The firm’s 50 day moving average is $73.59 and its two-hundred day moving average is $73.73. Bio-Techne Co. has a 52 week low of $61.16 and a 52 week high of $85.57. The firm has a market capitalization of $10.37 billion, a P/E ratio of 65.95, a PEG ratio of 5.54 and a beta of 1.27. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. Analysts anticipate that Bio-Techne Co. will post 1.68 earnings per share for the current year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 28th. Investors of record on Monday, February 17th will be paid a dividend of $0.08 per share. The ex-dividend date is Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.49%. Bio-Techne’s dividend payout ratio is presently 32.32%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Royal Bank of Canada raised their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a “sector perform” rating in a report on Thursday, February 6th. Robert W. Baird raised their target price on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Scotiabank raised their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 6th. StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, KeyCorp raised their target price on shares of Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $86.57.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Bio-Techne by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 18,594,608 shares of the biotechnology company’s stock valued at $1,339,370,000 after acquiring an additional 275,644 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Bio-Techne by 13.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,654,267 shares of the biotechnology company’s stock valued at $767,428,000 after acquiring an additional 1,229,954 shares during the period. State Street Corp increased its stake in shares of Bio-Techne by 1.5% during the third quarter. State Street Corp now owns 6,395,993 shares of the biotechnology company’s stock valued at $511,232,000 after acquiring an additional 95,133 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Bio-Techne by 7.2% during the fourth quarter. Ameriprise Financial Inc. now owns 4,702,942 shares of the biotechnology company’s stock valued at $338,756,000 after acquiring an additional 317,349 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Bio-Techne by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 4,001,296 shares of the biotechnology company’s stock valued at $287,488,000 after acquiring an additional 98,660 shares during the period. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.